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S'està fent un esforç notable a tot el món per trobar nous biomarcadors adequats per a 
l'esclerosi múltiple (EM). Es prioritari trobar una font d'informació estandarditzada i fiable que 
permeta no només un diagnòstic precoç i fiable, sinó també avaluar la resposta del tractament, 
i anar més enllà, com a manera de dilucidar el complex mecanisme immunològic subjacent a la 
EM. Un grup de miRNA pot ser el futur contribuent a aquest objectiu. Els microARN són petites 
molècules d'ARN monocatenàries no codificants que actuen com a reguladors post-
transcripcionals, silenciant l'ARN missatger (ARNm). Estan relacionats estrictament amb 
múltiples funcions indispensables, com la diferenciació cel·lular, la proliferació, l'apoptosi i el 
desenvolupament de teixits, i el que és més important en la EM, estan implicats en la regulació 
de la resposta immune, mitjançant la modulació i la diferenciació de les cèl·lules immunitàries, 
l'alliberament de mediadors inflamatoris i la producció d'anticossos. 
 
En aquesta revisió, ens centrem en quatre assajos clínics dirigits a canvis en l'expressió de miRNA 
durant o abans i després de diferents tractaments, per tal de valorar si són vàlids com a 
biomarcadors de resposta al tractament de la EM. Una cerca estructurada es va dur a terme en 
tres bases de dades (PubMed, the Cochrane Library i WebOfScience) i un cribratge posterior va 
donar lloc a la selecció final. Per avaluar la qualitat metodològica vam utilitzar el manual 
Cochrane per a revisions sistemàtiques d'intervencions (versió 5.1.0). Després d'elaborar aquest 
treball, vam arribar a la conclusió que els miRNA tenen aplicacions molt prometedores en aquest 
camp, però són necessaris estudis millor dissenyats per a confirmar noves troballes i identificar 
els miRNAs més sensibles i específics per avaluar la resposta al tractament. 
 
ABSTRACT 
A notable effort is being made worldwide in order to find the right biomarkers for multiple 
sclerosis (MS). It is a pressing subject to find a standardized and reliable source of information 
that allows not only an early and trusty diagnosis, but also to assess treatment response, and 
going further, as a way to elucidate the complex immunological mechanism underlying MS. A 
group of miRNAs might be the future contributors to this objective. MicroRNAs are small, non-
coding, single-stranded RNA molecules that act as posttranscriptional regulators, silencing 
complementary messenger RNA (mRNA). They are strictly related to multiple indispensable 
functions, such as cellular differentiation, proliferation, apoptosis and tissue development, and 
more importantly in MS, they are involved in the regulation of immune response, via modulation 
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and differentiation of immune cells, release of inflammatory mediators and antibody 
production.  
In this review, we center our focus on 4 clinical trials targeting changes in miRNA expression 
during or before and after different treatments, in order to assess whether they are valid as 
treatment response biomarkers in MS. A structured search was conducted in three databases 
(PubMed, The Cochrane library and WebOfScience) and a posterior revision yielded the final 
articles. To evaluate the methodologic quality we used the Cochrane Handbook for Systematic 
Reviews of Interventions (version 5.1.0). After elaborating this work, we conclude that miRNAs 
have very promising applications in this field, but better designed studies are much needed to 
confirm new findings and identify the most sensible and specific miRNAs to evaluate treatment 
response. 
























1.1 DEFINITION OF MULTIPLE SCLEROSIS  
Multiple sclerosis (MS) is an inflammatory, chronic and degenerative central nervous system 
disease characterized by an acquired demyelination and posterior axonal degeneration, caused 
by a combination of autoimmune, genetic and environmental factors. Thus, susceptible 
individuals if exposed to specific external triggers and/or endogenous antigens, develop an 
autoimmune cascade in which the myelin basic protein (produced by oligodendroglia) and 
ultimately axons are recognized as foreign and attacked by the immune system (1). The result is 
a severely damaged neuronal transmission with fatal consequences (2)(3). 
This pathology represents the most common nontraumatic cause of neurological disability in 
young adults, specially between 20 and 40-45 years of age, but it can also appear in children or 
in older adults. It affects women two to three times more than men. It is present worldwide, 
affecting more than two million people (4), but seems to be more prevalent in countries far from 
equator, as latitude represents the second risk factor after controlling for ethnicity (5), being 
good examples of high prevalence southern Australia and New Zealand, the Scandinavian 
countries, Canada, Northern Ireland and Scotland, but with exceptions such as Spain, Greece, 
Italy or Saudi Arabia, which are closer to the equator but have a medium-high prevalence as well 
(6). Incidence varies greatly even between provinces. The estimated incidence in Spain is 15-25 
cases for each 100.000 inhabitants/year (7). Up to date, there is no known cure for MS.  
Clinical manifestations of MS may range from modest to very serious neurological symptoms. 
Generally, MS is characterized by motor and sensory alterations. Motor symptoms include a limb 
or limbs that feel heavy, rigid, weak or clumsy, tremor, coordination impairment, bowel and 
urinary disorders, dysarthria, dysphonia and dysphagia. Frequent sensory symptoms reported 
are numbness, tingling, visual alterations, stiffness, fatigue and vertigo (8). Often MS is also 
accompanied by emotional and cognitive alterations and sexual disabilities.(9)   
These symptoms appear during or after a relapse or flare, which corresponds to the clinical 
manifestation of a new lesion in the CNS. The evolutional pattern of these flares is what drives 
the classification explained in the next section.  
In addition, the disease can follow different patterns depending on each case; some patients 
may only present a few relapses and stay relatively healthy for years or even decades, whereas 
in other cases, patients show a fast symptom worsening that can lead to a harsh reduction  -7 
to 14 years- in life expectancy (2). 
6 
 
The underlying reasons why myelin basic protein (MBP) and other myelin proteins are 
recognized by the immune system as foreign molecules remains unknown. It is generally 
accepted that that a group of myelin-specific autoreactive lymphocytes get activated by an 
unspecified environmental factor, which allows them to cross the blood-brain barrier (BBB) and 
cause havoc in the CNS.  IFN-γ producing CD4+ Th1 cells and IL-17 producing CD4+ Th17 cells 
seem to be primarily involved in the pathogenesis of MS (10); on the contrary, IL-4 producing 
CD4+ Th2 and IL-10 and TGF-β secreting CD4+ Treg cells suppress harmful mechanisms present 
in the disease (11). 
Once activated, T cells cross the BBB and, in the brain tissue, they get re-stimulated by APCs, 
leading to disease induction and progression. As disease worsens, more myelin antigens are 
presented by APCs (epitope spreading), leading to further activation of newly arrived T cells (12) 
which trigger an attack first to the myelin sheath and then the axons, leading both of these 
injuries to an impairing or interruption of nerve function, responsible for the clinical 
manifestations of MS (13,14). 
T cells were pointed for years as the main responsible for the development and progression of 
MS, but B lymphocytes are now “in the spotlight”, as they are able to present antigens and thus 
activate T cells much more efficiently than dendritic cells, one of the reasons why B-cell 
depletion with treatments like rituximab and ocrelizumab are often used in MS trials, and have 
shed some light on the implication of B lymphocytes in MS (15). B cells can secrete both 
proinflammatory (like IL-6) and anti-inflammatory (such as IL-10) cytokines, but in MS patients 
proinflammatory features tend to dominate (16). Oligoclonal bands (typically IgG, but IgM can 
be present) can be found in both the CSF or the parenchyma. They are a product of these B cells 
once they cross the BBB, where they also differentiate to plasmatic cells(17); microglia and 
oligodendrocytes can promote B-cell survival and thriving by the secretion of B cell activation 
factor (BAFF), a proliferation inducing ligand (APRIL) and IL-15. These antibodies have been 










Patients with multiple sclerosis can be classified in four main groups depending on the unfolding 
of the disease: 
1.  CLINICALLY ISOLATED SYNDROME (CIS)  
CIS is the definition received by the first clinical manifestation of a demyelinating lesion. Patients 
are classified in this group as long as they don’t develop another episode or attack or a new 
radiologic lesion.  
2.  RADIOLOGICALLY ISOLATED SYNDROME (RIS)  
A RIS consists of a lesion found incidentally that is compatible with MS in the brain and/or spinal 
cord but has not shown any clinical presentation or symptoms of the disease, and thus the 
patient doesn’t have any impairment related to MS. To be considered RIS, these findings should 
not be explained by another diagnosis, and the patient cannot have past or current clinical 
symptoms found on a neurological exam.  
3.  RELAPSING-REMMITING MULTIPLE SCLEROSIS (RRMS) 
                                                                                                                  
                                                                                                                                       
RRMS is the most common modality of the disease, affecting up to 80-85% of MS patients. 
Initially, there may be no symptoms at all, which can go along years before it is diagnosed, even 
when CNS lesions are already developed; this can be deducted when old lesions are found on 
MRI scans that don’t correlate with any clinical signs or symptoms recorded by clinicians or 
recalled by the patients themselves. What better defines RRMS, is that there is no progression 
in disability during periods of remission. It can be additionally classified as either active (with 
relapses and/or new MRI activity) or not active, and as worsening (with an increase in disability 
following a relapse/flare) or not worsening (9).  
Figure 1. Representation of the timeline of RRMS; following a relapse new symptoms 
may disappear without any increase of disability, or do so partially, resulting in a 
relative increase in disability. The duration of the episode and the duration of the 








SPMS appears in patients that already suffer RRMS, most of which will develop this form sooner 
or later. It is characterized by the persistence of disability or even worsening between relapses, 
and it is considered an advanced form of MS. Even though most patients can slow down this 
process with disease-modifying treatments, the disease keeps worsening, but can also present 
phases of relative stability. This MS variant can be classified or characterized as active (relapses 
and/or new MRI activity) or not active, as well as with progression (disease worsening over time, 
with or without relapses) or without progression.  




Figure 2. Representation of the timeline of SPMS. Relapses are relatively frequent, 
while disability tends to progress between relapses, with or without evidence of 
disease activity (clinical or MRI changes). Between relapses or progression without 
them there can be periods of stability (22). 
Figure 3. Representation of the timeline typically presented in this modality of the 
disease. PPMS can show brief periods of stability and have minor relapses, but what 
characterizes it the most is the increasing disability from onset (22). 
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PPMS affects around 10-15%(19)(20) of MS patients, having a near distribution between 
women and men (F:M 1.1–1.3 to 1) (21). It is characterized by an almost complete absence of 
recurrences, with a slow beginning and a progressive worsening of symptoms, without any 
remission between them. There can be stages of stability, but any improvement is typically mild 
and transient. As it doesn’t present major relapses, and most disease-modifying therapies center 
their effect on reducing inflammation in the CNS, it is the MS variant with the smallest response 
to the available treatments, since the core of the disease is nerve degeneration rather than 
inflammation.  





                                                     
 
 
PRMS is an infrequent presentation, affecting around 5% of patients with the condition. It is a 
combination of the progressive form with relapses. This classification has been proposed to be 
eliminated in recent guidelines, since it can be defined as a primary-progressive MS (PPMS) with 
disease activity (22). 
1.3 DIAGNOSIS 
The diagnosis of MS is made based on the McDonald criteria. They were defined by an 
international panel directed by William Ian McDonald jointly with the National Multiple Sclerosis 
Society, which recommended these revised criteria in 2001 (23). 
Since their publication, the criteria have been revised in 2005, 2010 and 2017, and nowadays 
they are considered the best directives to diagnose MS (24–26). 
 
 
Figure 4. Representation of the timeline of PRMS. This modality of the disease shows 




Table 1: The 2017 McDonald criteria for diagnosis of multiple sclerosis in patients with an attack at onset 
Clinical 
attacks 
Number of lesions with 
objective clinical evidence 
Additional data needed for a diagnosis of MS 
≥2  ≥2 None* 
≥2  
1 (as well as clear historical 
evidence of a previous attack 
involving a lesion in a distinct 
anatomical location†) 
None* 
≥2  1 
Dissemination in space implicating different CNS 
lesion sites visualized by MRI  
1  ≥2 
Dissemination in time demonstrated by MRI and /or 
additional clinical attacks OR demonstration of CSF-
specific oligoclonal bands ¶. 
1  1 
Dissemination in space AND time OR presence of 
CSF-specific oligoclonal bands ¶. 
Table 1. If the 2017 McDonald Criteria are fulfilled and there is no other explanation for the clinical 
symptoms the diagnosis is MS. If MS is suspected but the 2017 McDonald Criteria are not completely 
met, the diagnosis is possible MS. If another diagnosis arises during the evaluation that better explains 
the clinical presentation, the diagnosis is not MS. *No additional tests are required to demonstrate 
dissemination in space and time. Brain MRI should be obtained in all patients where MS diagnosis is 
being considered. In addition, spinal cord MRI or CSF examination should be carried out in patients 
with insufficient clinical and MRI evidence supporting MS with a presentation other than a typical 
clinically isolated syndrome, or with atypical features. If imaging or other tests (eg, CSF) are negative, 
alternative diagnoses should be considered. † Clinical diagnosis based on objective clinical findings for 
two attacks is most secure. Reasonable historical evidence for previous inflammatory demyelinating 
attack, in the absence of documented neurological findings, can include historical events and patient 
and family recollection of symptoms. However at least one episode must be supported by objective 
findings, otherwise caution is needed. ¶The presence of CSF-specific oligoclonal bands can substitute 
for the requirement for demonstration of dissemination in space and time. 
 
Initially, using the McDonald criteria, MS was diagnosed only by the clinical manifestations of 
the disease. Nowadays, both clinical symptoms and image techniques to visualize CNS lesions 
are used for diagnosis. Magnetic Resonance Imaging (MRI) is widely used to see lesions in white 
matter that are characteristically enhanced in T2 sequences. Generally, T2 sequences provide 
information about disease burden or lesion load (the total area affected by new and old lesions), 
while T1 sequences grant information about current disease activity, as it highlights areas with 
active inflammation.  
In the most recent revision of the McDonald criteria, a third diagnostic tool, cerebrospinal fluid 
(CSF) examination has been suggested to increase diagnostic confidence as the evidence of 
presence of intrathecal antibodies (oligoclonal bands) supports MS diagnosis. On the other 
hand, atypical findings in the CSF, such as pleocytosis (an increase in white blood cell count), 
elevated protein concentration or atypical cells may be associated to a different disease. CSF 
examination is especially useful in the following cases: 
• When clinical and MRI evidence are insufficient to support a diagnosis. * 
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• When there is clinical presentation other than a CIS, including a progressive course at 
onset (PPMS). 
• When clinical, imaging or laboratory results are atypical of MS. 
• Groups where MS is less common (children, non-white or older individuals). 
*Particularly if starting any disease-modifying therapies is contemplated.  
Even though cerebrospinal fluid specific oligoclonal bands are decisive to diagnose MS in 
different situations (see table 1) (26) and their non-existence has a very high negative predictive 
value, still their absence does not dismiss MS. Thus alternative diagnoses must be investigated 
in such situations, but keeping in mind that early stages of the disease and children do not always 
show CSF-OCB (27). 
1.4 ETIOPATHOGENY 
1.4.1 GENETIC FACTORS 
A genetical disorder underlying the onset of the disease is widely accepted because familiar 
recurrence is observed, and if the father has suffered MS it is generally more devastating in its 
descendance. When first degree relatives are affected, the risk of developing MS is multiplied 
15 to 35 times (5). 
Relatedness Recurrence 
Monozygotic twins 25.3%* (SE ± 4.4)(28) 
Heterozygotic twins 5.4% (±2.8)(28) 
Non-twin brothers 2.9% (±0.6) (28) 
Both parents affected by MS 12.2%(29) 
One parent affected by MS 2-5%(30) 
 
Particular chromosomal regions have been related to the disease, specifically in the short arm 
of the chromosome 6 (6p21-23); located in this region, the human leukocyte antigen complex 
encodes for HLA-DR, an MHC class II cell surface receptor. In northern Europe, HLA-DR2 and 
more importantly HLA-DRB1*15 variants have been associated with MS (8)(31). 
Interestingly, Sardinia (Italy) has a very high prevalence of the disease, where HLA-DRB1*0301, 
HLA-DRB1*0405 and HLA-DRB1*1303 have been related to higher MS prevalence. Other genes 
related to a greater susceptibility to develop MS are interleukin 2 receptor alpha (IL2RA); tumor 
Table 2. Recurrence of MS depending on the familial relatedness. *Recurrence 
rate can vary greatly depending on the study, ranging from 5,9 to 50% (28). 
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necrosis factor receptor superfamily member 1A (TNFRSF1A), a main regulator of inflammation; 
IRF8 (Interferon regulatory factor 8), related to the regulation of lineage commitment and in 
myeloid cell maturation; cell adhesion antigen 58 (CD58) also called lymphocyte function-
associated antigen 3, present in APCs such as macrophages); Ecotropic viral integration site 5 
(Evi5), that belongs to a small subfamily of the Tre-2/Bub2/Cdc16 (TBC) domain-
containing proteins and has been shown to increase susceptibility to MS, in particular in HLA-
DRB1 positive patients;  Iinterleukin-7 receptor α chain (IL7RA); CD6 (present in T-lymphocytes 
and other immune cells);  and C-type lectin domain family 16 (CLEC16A), highly expressed on B-
lymphocytes, NK and dendritic cells, with a poorly understood function so far (32)(33). 
1.4.2 ENVIRONMENTAL FACTORS 
Although it is undeniable that genetics are key determining the susceptibility to suffer MS, the 
importance of environmental factors is also recognized for disease development. As described 
earlier, monozygotic twins (that by definition share the same genome) can show a huge variation 
in concordance rates, suggesting that other not inheritable factors may be necessary for the 
initiation of the autoimmune response. There are several microbiologic and non-infectious 
precipitants identified as MS risk increasing factors.  
INFECTIOUS FACTORS 
The most studied infectious element related to MS is the Epstein-Barr virus (EBV), which belongs 
to the Herpesviridae family. This virus has been associated to infectious mononucleosis (IM) and 
to the onset of different types of cancer such as nasopharyngeal carcinoma, among many other 
entities (34). However EBV has been mostly associated to lymphoproliferative diseases such as 
Burkitt’s and Hodgkin’s lymphoma (35). EBV infects B lymphocytes, where it persists in resting 
B cells (memory B cells) for the rest of the host’s lifetime, allowing a chronic T cell cytotoxic 
response and the persistence of anti-EBNA titers (EBV nuclear antigen IgG) that usually remain 
stable throughout life (36). 
There is cross-sectional evidence where people with a history of EBV infection or acute IM 
acquire an increased risk to develop MS. For a person with IM history, a 2.3 fold increased 
relative risk of MS has been observed against those without EBV infection (95% CI) 1.7–3.0; 
p<10−8(37). Similarly, another meta-analysis found  that  the risk of developing MS following IM 
was higher (RR of 2.17 (95% CI) 1.97–2.39; p<10−54 (38)). In addition, EBV positive patients show 
a risk 15 times higher than EBV-negative individuals when acquired in childhood and 30 times 
higher among those infected in adolescence or later (39). The previous results are reinforced by 
longitudinal evidence; in a study where 200,000 individuals where followed for seroconversion 
to EBV and MS incidence, all the documented cases of MS in EBV positive individuals (10 cases 
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in 200,000), were positive for the virus prior to the development of MS symptoms, adding 
temporal data to the available evidence (40).  
NON-INFECTIOUS FACTORS 
Three main non-infectious factors have been related to MS: scarce UV light exposure, low 
Vitamin D levels, and smoking.  
VITAMIN D 
Vitamin D is a liposoluble secosteroid essential for calcium metabolism and bone mineralization, 
but it is also known to mediate multiple physiological functions as a hormone when in its active 
form (1,25-dihydroxyvitamin D, also known as calcitriol) binding to its intracellular receptor, 
which ultimately regulates the expression of several hundred genes (at least 500), some of them 
involved in immunomodulation, and therefore especially valuable for  MS.  
Vitamin D was first brought into discussion because there is a clear latitudinal gradient of MS 
prevalence, as UV light penetrance required for vitamin D synthesis declines vastly as we get far 
from the equator, which might explain MS distribution worldwide (higher prevalence with less 
sunshine, but not always, as described at 1.1), and also the fact that MS risk decreases for 
individuals who migrate from places far from the equator to closer ones (41). Vitamin D levels 
are very dependent of sunlight exposure, as it is the main source for humans, with a low 
contribution from dietary sources that is limited to fortified foods, fatty fish or derivates and 
vitamin supplements (42).  
Calcidiol or 25-(OH)-D is a prohormone produced in the liver by hydroxylation of vitamin D3,  
given its long half-life (20 to 60 days), calcidiol concentration is used for analysis, giving more 
information about the reserves in the body and translating more precisely the measure of 
vitamin D coming from both diet and UV-B exposure (43). Normal physiological serum 25-(OH)-
D levels range from 30 to 60ng/mL; studies in Swedish pregnant women have found an inverse 
relationship between serum 25-(OH)-D levels and MS risk, where levels above 30ng/mL had a 
61% lower MS risk than those with less than 30ng/mL (44). This effect was observed in newborns 
too, where a 25ng/mL elevation in neonatal 25-OH-D serum level was associated to a 30% 
reduction in risk to develop MS 15-30 years later (OR 0.70, 95% CI 0.57–0.84)(45). 
UVB LIGHT 
UV light exposure was mentioned at the beginning of this section along with Vitamin D because 
it is a potential confounder, as it is very difficult to separate both as most of the vitamin D is 
obtained through exposure to this type of radiation. UV-B light has direct immunomodulatory 
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effects through induction of skin-derived tolerogenic (IL-10-producing) dendritic cells and 
regulatory T cells, confirmed by skin biopsies from MS patients exposed to UV-B phototherapy 
(46), so the immunomodulatory effects of vitamin D could be less potent than thought.  
UV-B light is the most important on a physiological level since it is the only fraction of the light 
spectrum that promotes vitamin D synthesis in the skin; however excess UV-B is deleterious,  
causing DNA damage through inducing a cascade of cytokines, vasoactive and neuroactive 
mediators that altogether create an inflammatory response that leads to the sign and symptoms 
known as “sunburn”(47).  
TOBACCO SMOKING 
Smoking has been elevated to a subject of main interest as a risk factor for MS and also as very 
influencing on disease progression. Because it represents a completely modifiable exposure, it 
seems a priority to give patients every help and recommendation they need to abandon this 
addictive and pernicious product. The prospective studies Nurses Health Study I and II have 
shown that smoking is a risk factor for MS, obtaining a RR of 1.7 (95% CI: 1.2-2.4, p<0.01) for 
women who smoked 25 or more pack-years compared to individuals that never smoked, even 
controlling for ancestry and latitude. Furthermore, smoking is associated with a faster transition 
from CIS to confirmed MS, increases the risk of conversion from RRMS to SPMS and a quicker 
neurological loss with greater clinical disability in progressive phases (36).  
1.5 THE PAPER OF MicroRNAs 
MicroRNAs (miRNA) are a type of small, non-coding RNA molecules with a length comprised 
between 19 and 22 nucleotides disposed in a simple strand. They act as posttranscriptional 
regulators, silencing complementary messenger RNA (48). 
miRNAs regulate a myriad of cellular events, differentiation, proliferation, apoptosis and tissue 
development. In addition, miRNAs are involved in the regulation of immune response, via 
modulating growth and differentiation of immune cells, antibody and inflammatory mediator 
production. Accordingly, dysregulation of miRNAs expression could lead to multiple biological 
alterations and pathologies, including MS.  
The use of miRNAs as biomarkers in MS has acquired special attention in the past 10 years. They 
can be isolated from peripheral blood mononuclear cells (lymphocytes and monocytes), immune 
cells, serum itself and cerebrospinal fluid. Differences in miRNA levels have been correlated to 
relapses, disease severity and response to some treatments (i.e. natalizumab) (11).    
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1.5.1. DYSREGULATION OF miRNAs IN MS 
miRNAs are involved in the development of any acute inflammatory reaction since they are 
direct regulators of antibody production in B cells and also intervene in the release of 
inflammatory cytokines. miRNA can be classified as anti-inflammatory or pro-inflammatory, 
depending if their function is to promote inflammatory response (ie upregulating anti-
inflammatory cytokines or degrading pro-inflammatory cytokines, respectively). Thus, 
deregulation of miRNA will influence inflammatory status. Some of the miRNAs implicated in the 
autoimmune war present in MS are the following: 
• miR-16: (anti-inflammatory) is normally highly expressed in cells involved in the 
inflammatory response (monocytes, B lymphocytes, both CD4 and CD8 T cells and 
neutrocytes). When correctly regulated, it intervenes in the degradation of mediators 
like IL-6 and TNF-α. 
• miR520/373: (anti-inflammatory) reduces the expression of inflammatory cytokines (IL-
6 and IL-8), thus inhibiting signaling pathways triggered by NF-KB (a transcription factor 
that controls antibody transcription) (49).  
• miR-146 and miR-155: (proinflammatory) derived from the activation of TLR4, leading 
to the signaling pathway of NF-KB and cytokine production (50)(51).  
• miR-146a: (anti-inflammatory) has been identified as key in the regulation of innate 
immunity and critical for the suppressor function of T regulatory cells (52). 
• miR-126: (anti-inflammatory) is related to the regulation of VCAM-1 in endothelial cells, 
thus its downregulation increases the presence of this adhesion molecule, increasing 
leukocyte adhesion and neuroinflammation (53).  
• miR-31: (pro-inflammatory) it negatively regulates FOXP3, the master of Treg 
lymphocyte development and function (54). 
There are dozens of other miRNAs involved in the inflammatory response and perpetuation in 
MS and other autoimmune diseases. Some of the miRNA in this list will be mentioned in the 
results and discussion sections.  
3.STUDY JUSTIFICATION AND OBJECTIVES 
Multiple sclerosis is an unpredictable, uncurable and disabling disease that can alter every 
dimension of a patient’s life. Approved disease modifying treatments reduce the frequency and 
severity of relapses, and in RRMS, treatments can reduce the accumulation of lesions in the CNS, 
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but they have very little effect in the progressive forms of MS, in which a lot of patients end up 
being classified (55).  
As miRNAs seem to have great potential as diagnostic and prognostic biomarkers, the objective 
of this work is to perform a systematic review of the available evidence regarding miRNA 
expression in response to different treatments (disease modifying therapies and alternative if 
any), to assess if  any of them responds commonly to the different pharmacological approaches 
and thus identify new trusty biomarkers for MS. 
Specific investigation questions for this review are: 
-¿Are there expression changes in miRNA after any pharmacological treatment of MS? (and 
therefore, considered as biomarkers of treatment response). 
-¿Is there any similitude between expression changes in conventional disease modifying 
therapies and alternative therapies in MS? 
4.METHODS  
4.1 SEARCH STRATEGY  
The PRISMA-P statement was followed to conduct this search. As this systematic review is 
focused on a variety of treatment strategies and miRNA expression, the following search terms 
were used to search all trials in the PubMed database: 
a) The first one, with the MeSH terms "multiple sclerosis" AND "microRNA" yielded 296 results. 
Then, the search was modified to ((Multiple Sclerosis) AND Micro RNA) AND Trial, which 
narrowed down the results to 6 articles.  The “published in the last 10 years” filter was 
applied, which didn’t change the results.  
The following search terms and filters were applied to search all trials in the Cochrane Library 
database: 
b) The same terms were used for the search, that is “Multiple Sclerosis” and “microRNA”, 
which yielded 5 total results and 3 results at the “trials” tab. Then, a temporal filter was 
applied to obtain results published only in the past 10 years, which didn’t change the results. 




c) The search terms “Multiple Sclerosis” and “microRNA” were used, which yielded 575 results. 
The term “clinical trial” was added to the search, which yielded 5 results. The temporal 
publication filter was set to the past 10 years, which didn’t change the results. 
These three searches were performed repeatedly from 24/01/2019 to 15/05/2019, with no 
variations in the final outcome.  
4.2 SELECTION CRITERIA  
• As inclusion criteria: 
- Patients diagnosed with Relapsing-remitting multiple-sclerosis (RRMS).  
- Samples withdrawn preferably before and after but at least after or during any treatment 
for RRMS. 
- Presence of a control group.  
- Analysis of microRNA expression. 
• As exclusion criteria: 
- Papers that don’t focus on multiple sclerosis. 
- Duplicates. 
- Studies performed on animals. 
- Studies published more than 10 years ago.  
After the preliminary revision of all articles obtained with all the filters applied, a total of 4 
articles were selected: 
• “Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing 
Remitting Multiple Sclerosis” by Waschbisch A et al. 
• “Altered microRNA expression in B lymphocytes in multiple sclerosis towards a better 
understanding of treatment effects” by Claudia Sievers et al. 
• “Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing 
inflammatory mediators” by Sanam Dolati et al. 
•  “Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, 




















                       
  
 
4.3 DATA EXTRACTION 
For a proper gathering and simplification of all the data of interest, a table was designed 
containing the following: 
• Author, journal and date of publication. 
• Country where the study has been conducted. 
• Type of study. 
• Objectives. 
• Number of patients that participated (dividing each group). 
• Number of losses if any.  
• Treatment received 
• Results  
• Conclusion 
• Levels of evidence: SIGN grading system for randomized controlled trials (56) and USPSTF 
for non-randomized trials (57) (supplementary figures 4 and 5 respectively).  
• Methodologic quality: evaluated using the Cochrane Handbook for Systematic Reviews of 
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Figure 5. Flowchart illustrating the search steps for this review. 
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Table 3. Main characteristics of the analyzed studies. RRMS: relapsing remitting multiple sclerosis. HV: healthy volunteers.
Author, journal 
and date 
Country Type of 
study 
Objectives Sample size Losses Treatment 
received 
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5.1 SUMMARY BY ARTICLE  
ARTICLE 1. Anne Waschbisch et al. PLOS ONE 6(9): e24604. 2011 . “Glatiramer 
acetate treatment normalizes deregulated microRNA expression in relapsing 
remitting multiple sclerosis”.  
After informed consent, a non-randomized controlled trial was performed with a total of 106 
individuals (74 RRMS patients and 32 healthy volunteers), >97% of Caucasian origin.  
 
 
Regarding the RRMS patient group, 36 were treatment-naïve, 18 were treated with Interferon-
beta (Avonex® n = 5, Rebif® n =8, Betaferon® n =5) and 20 were treated with Glatiramer-acetate 
(Copaxone®), both treated groups followed the therapies for at least 3 months. As a control 
group, 32 healthy volunteers were enrolled.  
Blood samples were drawn from all the participants and were rapidly processed for isolation of 
peripheral blood mononuclear cells (PBMC). The specifics about PBMC processing, miRNA 
isolation and posterior Real-Time PCR are summarized in the original article (52). 
RESULTS BY GROUPS: HEALTHY VOLUNTEERS AND TREATMENT NAÏVE RRMS PATIENTS 
After processing and isolation of miRNA, expression was studied in five selected by the authors 
(miR-20b, miR-142-3p, miR-146a, miR-155 and miR-326) in treatment naïve RRMS patients and 
healthy controls (HC).  No significant difference in the expression of miR-20b (a member of miR-
106a cluster, which characteristics are briefly described in the next summary) was found, but 
the expression of the rest miRNA was multiplied by 2 to 3 in treatment naïve patients in 
comparison to HC. Interestingly,  miR-326 is overexpressed during relapses but falls down to 
normal levels in remission states, so it has been proposed as a biomarker for relapse and 
remission phases in patients with RRMS (58). 
Table 4. Clinical and demographic details of patients and healthy controls. 
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RESULTS BY GROUPS: GLATIRAMER ACETATE AND INTERFERON-BETA TREATED PATIENTS 
VS TREATMENT NAÏVE PATIENTS 
The expression of the previously described miRNAs did not differ between IFN-β and treatment 
naïve (TN) patients, but it did in glatiramer acetate (GA) treated patients, specifically the 
expression of miR-142-3p (p=0,003) and miR-146a (p=0,028) was decreased to values similar to 
their normal levels, while miR-155 and miR-326 were comparable between GA and TN patients.  
In other words, this study would support the predictive value of miR142-3p and mir146a, but 
not miR-155 and miR-326. 
Interestingly, in vitro stimulation of PBMC derived from treatment-naïve patients with 
glatiramer acetate during 72 hours (with a of 40 µg/ml dose) did not result in the downregulation 
of the reviewed miRNAs, inferring that a more complex immunological process needs to occur 
for these mechanisms to function the way they do in vivo.  
ARTICLE 2. Claudia Sievers et al. CLINICAL IMMUNOLOGY 144, 70–79. 2012.   Altered 
microRNA expression in B lymphocytes in multiple sclerosis.  
After informed consent, a non-randomized controlled trial was performed with a total of 89 
individuals: 
Profiling group Validation cohort 
10 untreated RRMS patients* 
10 treated with Natalizumab  
10 healthy age and gender 
matched volunteers 
30 untreated RRMS patients* 
22 treated with Natalizumab 
7 healthy volunteers 
All untreated patients received no MS specific treatments in 6 months before or throughout the 
course of this study, and all the patients treated with natalizumab were responders (assessed 
by clinical changes). 
After blood was drawn, B lymphocytes where isolated by a physical method and then analyzed 
by flow cytometry for purity. RNA isolation and profiling, target prediction and miRNA/mRNA 
expression analysis are all described in detail in the original article (59). A total of 1059 miRNAs 
were tested in B cells from the profiling group.  




RESULTS BY GROUPS: EXPRESSION OF miRNAs IN UNTREATED PATIENTS VS HEALTHY 
CONTROLS 
49 miRNAs were significantly downregulated in B-cells of untreated RRMS patients compared 
with healthy controls, and no significantly up-regulated miRNAs were found. Among the 
downregulated miRNAs, three members of the miR-106b-25 cluster were identified (miR-25, 
miR-106b and miR-93). Interestingly, this family of microns is found altered (down or up) in 
multiple affections such as different types of cancer, cardiac hypertrophy and MS (60)(61). Also, 
a member of the miR-17-92 cluster (miR-19b) was identified. This miRNA family is related to the 
negative regulation of NF-Kb, linked to chronic inflammation in rheumatoid arthritis (62). Two 
other miRNAs selected in the study where identified, miR-181a (an intrinsic modulator of T Cell 
sensitivity and positive and negative selection (63)); and miR-93, which contribution to MS in 
humans is still to be elucidated (64). Also 3 viral miRNAs (EBV-miR-BART7, BART19-5p and 
BART11-5p) were down-regulated.  
 
RESULTS BY GROUPS: EXPRESSION OF miRNAs IN NATALIZUMAB TREATED PATIENTS VS 
UNTREATED RRMS PATIE NTS 
6 months after initiating the treatment with natalizumab, 10 miRNAs were upregulated in 
treated compared with untreated RRMS patients. Half of them (miR-106b, miR-19b, miR-551a, 
miR-191 and EBV-BART11-5p) were upregulated comparing untreated RRMS patients with 
healthy volunteers, but significantly downregulated in natalizumab treated patients versus 







Figure 6. Differentially expressed miRNAs in B lymphocytes between groups. Green circle 
corresponds to healthy volunteers. Red circle represents patients treated with natalizumab. 
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In the follow up of natalizumab treated patients 12 months after starting the treatment, miR-
19b expression remained stable in 5 out of 8 patients, while miR-106b expression was 
downregulated in 7 out of 8 patients.  
From these results, we can assume natalizumab has a direct impact on miRNA regulation, at 
least in miR-106b, miR-19b, miR-551a, miR-191 and EBV-BART11-5p, as they almost normalize 
after treatment compared to untreated RRMS patients.  
ARTICLE 3. SANAM DOLATI ET AL. JOURNAL OF CELLULAR PHYSIOLOGY. VOL 233, 
ISS. 7. P5222-5230. JULY 2018. NANOCURCUMIN RESTORES ABERRANT MIRNA 
EXPRESSION PROFILE IN MULTIPLE SCLEROSIS, RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED TRIAL. 
A randomized, double-blind, placebo-controlled trial was performed with a total of 50 patients 
and 35 healthy volunteers. After losses, the final distribution was 20 RRMS patients treated with 
nanocurcumin, 21 patients assigned to placebo and 35 healthy controls. Informed consent was 
obtained prior to participating.  
The objective of this study was to analyze miRNA expression (obtained by qPCR) at the beginning 
of the trial and after 6 months of treatment with nanocurcumin, as a way to find the 
immunomodulatory impact of this polyphenol on miRNA expression.  
For this purpose, blood was drawn (10-15ml) to all patients prior to the administration of 
nanocurcumin or placebo capsules (1 daily) for the next 6 months. Healthy volunteers only had 
to provide one blood sample at the beginning of the study.  
RNA extraction methods and qPCR analysis of miRNA expression are described at the original 
paper (65). 
RESULTS BY GROUPS: RRMS PATIENTS AT BASELINE VS HEALTHY CONTROLS 
27 miRNAs from all RRMS patients and controls were analyzed at baseline.  
This analysis revealed 13 upregulated miRNAs in RRMS patients: miR-16, miR-17-5p, miR-17-92, 
miR-27, miR-29b, miR-126, miR-128, miR- 155, miR-326, miR-340, miR-550, and miR-340 in CD4+ 
T cells and mir-132 in B cells, compared with healthy controls.  
The analysis also unveiled 16 downregulated miRNAs: miR-15a, miR-16-1, miR-18a, miR-20b, 
miR-25, miR-106b, miR-363, miR-31, miR-181c, miR-374a and miR-150 in CD4 T cells and in miR-
16, miR-19b, miR-320a, miR-340 and miR- 599 in B cells of untreated RRMS patients compared 
with healthy controls.  
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RESULTS BY GROUPS:  NANOCURCUMIN VS PLACEBO GROUP 
Nanocurcumin treatment significantly decreased the expression of the upregulated miRNAs 
listed above compared with the placebo group (complementary figure 1) with two exceptions in 
miR-17-5p and miR-223 which showed no significant changes.  
Regarding the downregulated miRNAs, the expression of miR-15a, miR-16, miR-19b, miR-106b, 
miR-320a, miR-363, miR-31, miR-181c, miR-150, miR-340, and miR-599 was significantly raised 
in nanocurcumin treated RRMS patients compared to the placebo group (compl. figure 2).  
From these results it is assumable that nanocurcumin has direct positive effects on multiple 
miRNAs, turning their expression almost back to normal in some cases, which might open the 
path to bigger and strongly built clinical trials in the near future, since it is a seemingly innocuous 
substance (no systemic adverse effects were observed during the 6 month treatment with 
nanocurcumin).  
ARTICLE 4. SANAM DOLATI ET AL. PHARMACOLOGICAL REPORTS. VOL 70, ISSUE 6, 
PAGES 1158-1167. DEC 2018. NANOCURCUMIN IS A POTENTIAL NOVEL THERAPY 
FOR MULTIPLE SCLEROSIS BY INFLUENCING INFLAMMATORY MEDIATORS.  
Even though the patient sample seems to be the same for this study and the previously 
summarized, differences in design have been spotted looking deeper in their execution, there 
are different authors in both publications, and as this study targets one miRNA not analyzed in 
the previous study. In addition, this study evaluates miRNA dependent targets. 
A randomized, single-blind, placebo-controlled trial was performed with a total of 50 patients 
(at start) and 35 healthy volunteers. After losses, the final distribution was 20 RRMS patients 
treated with nanocurcumin, 21 patients assigned to placebo, and 35 healthy controls. 
Demographic details are summarized in the complementary figure 3.  Informed consent was 
obtained prior to participation. The objective of this study was to identify the effects of 
nanocurcumin on inflammatory mediators in patients with RRMS.  For this review, we will only 
focus on the miRNA analyzed and their targets, which were miR-132, miR-145 and miR-16.  
PBMC isolation, RNA extraction methods, cDNA synthesis and RT-PCR used for the assessment 
of miRNA expression are described at the original work (66). The expression levels of miR-145, 
miR-132 and miR-16 dependent targets were analyzed before and after 6 months of treatment 
with nanocurcumin or placebo.  
In the nanocurcumin group, the expression of miR-145 was significantly decreased compared 
with baseline. At endpoint, the expression of this miRNA was significantly higher in the placebo 
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group compared with the treatment group (0.94 ± 0.15 versus 0.32 ± 0.17, p<0.0001). The target 
of miR-145 is Sox2, a transcription factor crucial for oligodendroglial proliferation and 
differentiation, necessary for myelin formation and repair in multiple sclerosis and other myelin-
related neurological disorders (67). The expression level of Sox2 was increased in the 
nanocurcumin group compared with baseline and with the placebo group. 
Along the same path, miR-132 expression was decreased in the nanocurcumin group compared 
with baseline, and also with the placebo group (1.05 ± 0.25 in placebo vs 0.69 ± 0.29 in 
nanocurcumin, p=0.0039).  The  target of miR-132 is sirtuin1, which is known to regulate, among 
many other things, the NFkB-light-chain-enhancer of activated B cells and biological processes 
related to axonal integrity (68), reason why it has been proposed as a potential biomarker of 
response to treatment in MS (69).  Accordingly, the expression level of sirtuin1 was significantly 
increased after treatment with nanocurcumin compared with baseline and also the placebo 
group. 
Finally, miR-16 expression was significantly reduced in the nanocurcumin treated group 
compared with baseline, but with no significant differences between the treatment and placebo 
group (p=0.69). miR-16 dependent targets are Foxp3 (like miR-31, described in 1.5.1.) and 
PDCD1 (programmed death-1, an inhibitory receptor on antigen activated T-cells that plays a 
critical role in induction and maintenance of immune self-tolerance)(70). Even after finding no 
significant differences between the treatment and placebo group in terms of miR-16 expression, 
its targets were significantly increased in the nanocurcumin group compared to baseline and the 
placebo group. These results suggest a direct impact of nanocurcumin on miRNA expression 
and/or their molecular targets, opening a new path of investigation for the treatment of MS.  
In regard of clinical changes, EDSS scores (Expanded Disability Status Scale (74), the most used 
disability quantification method In MS patients) were measured before and after treatment with 
nanocurcumin and placebo, yielding a significative improvement in the EDSS score of 
nanocurcumin treated patients, although they had low disability at baseline, but still had a 
significative difference with the placebo group (results are in complementary figure 6).
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Table 6. Assessment of the methodological quality according to the Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). 
(i) The sample origin is not withdrawn, and no reference to any sequence generation is disclosed. The selection criteria can be partially deducted (treatment 
assigned or absence of it, being a healthy individual for the controls) but are not described in the papers. 
(ii) Patients were already in treatment by their neurologists at the beginning of the study. There isn’t a placebo group.  
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(iii) There was not any blinding, but because of the study design and absence of conflict of interest of the main investigators, we don’t think it is a significant 
source of bias.    
(iv) Blinding of outcome assessors is not mentioned.  
& As patients were already on treatment by their neurologists, their blinding is unnecessary.  
# Because of the multiple conflicts of interest (the main investigator (AW) has received funding for travel or speaker honoraria from all the companies that 
manufacture the investigated drugs (Teva: Copaxone, Bayer: Betaferon, Biogen: Avonex, Merck: Rebif), while others have also received funding from these 
companies and others), we think the blinding in personnel and outcome assessors should have been used for this trial in order to reduce potential bias.  
* Randomization is mentioned in the title but not in the rest of the article. There is a table where patient characteristics are displayed, but there’s no mention 
to the randomization type.   
¥ There is no mention about allocation concealment. Double-blinding is mentioned in the title, but again, not in the rest of the article. Nothing is mentioned 
about the placebo appearance besides it being in capsule form (the real treatment is also in capsule form).  
£ The only mention about blinding is in the title, as “double-blind”. No other reference in the rest of the paper, but it is specified as double blinded (participant 
and care provider) in the clinical trial registry.   
¶ As the only mention is “double-blind”, we have to assume they mean blinding of both participants and personnel, but not outcome assessors. 
€ Blocked randomization was used. ** 
Ω According to the investigators single blinding was used, so they knew who got treatment or placebo, and no description of the placebo is provided besides 
it being in capsule form, and at one point in the paper they describe the actual treatment as a “softgel”, then refer to it as in capsule form too, so it is highly 
unclear. ** 
∫ The clinical trial register says single blinding was used, so the participants didn’t know if they were getting placebo or the real treatment, but the authors 
apparently did ** 
∏ The study did not address this outcome. ** 
 




The diagnosis of multiple sclerosis is fundamentally based in clinical procedures (medical history 
and neurological exam), MRI imaging and cerebrospinal fluid analysis. Other frequently used 
tools are evoked potentials (to assess demyelination) and optical coherence tomography (to 
analyze optic nerves, mapping retinal structure). All these instruments have proven their value, 
but there’s still need for new appliances that are able to measure relevant outcomes in 
treatment response, especially for monitoring response to disease modifying drugs. In this 
regard, most clinical trials register either clinical or MRI aspects of multiple sclerosis, but 
biomarkers lack a proper flagship when speaking about treatment response, since oligoclonal 
bands in cerebrospinal fluid (CSF) have a great prognostic value (their absence is related to a 
more benign course, and their presence with a higher probability of progression from CIS to 
clinical MS) but they are not affected by therapeutic agents; in fact, they tend to persist in the 
CSF after B-cell depletion using Rituximab (71) (an Anti-CD20 monoclonal antibody), or even 
after an autologous hematopoietic stem cell transplantation (72). Another problem related to 
OCB is that a lumbar puncture is needed to obtain CSF samples, which is invasive and if needed 
to perform repeatedly can become very unpleasant for the patient. In this path, numerous CSF 
parameters are being investigated as biomarkers, such as factors of inflammation, 
demyelination, remyelination, repair and neuronal damage. 
Interestingly, polyspecific antibodies against measles, rubella and varicella zoster -so called the 
MRZ antibody reaction- are becoming a more specific but less sensitive biomarker for MS, since 
they predict better (with a higher positive predictive value) the conversion from CIS to MS than 
MRI or oligoclonal bands. Other antibodies related to MS treatment are those generated against 
disease modifying treatments like natalizumab and IFN-β, which affects their bioactivity, or Anti-
JC virus antibodies, which high titers are related to an elevated overall incidence of progressive 
multifocal encephalopathy, especially if natalizumab therapy is extended for years. But as for 
treatment response, options are generally lacking applicability.  
We have performed a systematic review about multiple sclerosis since it is an incurable disease 
to this day, and centered around miRNAs because they are a flourishing line of investigation for 
a myriad of illnesses. miRNAs in MS seem to have a place, at least as dynamic markers of 
biochemical treatment response and disease status (58), but bigger and better designed studies 
are much needed for miRNAs to become a reliable and standardized tool in this field, be it as 
diagnostic or as prognostic markers. And perhaps therapeutic targets. We have found 4 
registered clinical trials specifically focused on miRNA expression analysis in response to 
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different treatments: Ocrelizumab (anti-CD20 monoclonal antibody) with a cohort design and 
130 participants, an open label study with recombinant IFN-β (Rebif and Avonex) in 50 
participants, a randomized, double blind but not controlled trial with Vitamin D in a target 
sample size of 95 individuals, and another randomized, double blind, placebo controlled trial 
using nanocurcumin. Access to these trials is listed right after the reference list.  
For this work, 4 studies were selected (52,59,65,66) fulfilling inclusion and exclusion criteria, in 
which patients had been diagnosed with MS (specifically RRMS, the most common 
presentation), and treated with multiple pharmacological and alternative approaches 
(glatiramer acetate, IFN-β, natalizumab and nanocurcumin).  
All the studies selected are centered around the analysis of miRNA expression during or before 
and after treatment. For this purpose, in all of the studies reviewed (54,56,62,66) blood samples 
were withdrawn for PBMC isolation, cultivation and PCR procedures to amplify the target 
miRNAs.  
In all four studies expression patterns in miRNA changed after treatment; with glatiramer 
acetate (partially restoring the expression of miR-146a and miR-142-3p), natalizumab 
(enhancing the expression of miRNAs downregulated in untreated RRMS patients acting as 
controls, affecting miR-19b, miR-551a, miR-106b, miR-191 and EBV-miR-BART11-5p) and 
nanocurcumin (influencing several miRNAs and quite frequently downregulating the 
upregulated and upregulating the downregulated, with encouraging results but with a study 
design with room for improvement).  
After displaying study results, the most important matter is trying to answer the investigation 
questions raised earlier in this review. As for if there are expression changes in miRNA after any 
pharmacological treatment, we can extract from Waschbisch et al. that MS patients receiving 
treatment with glatiramer acetate have a different miRNA expression pattern than treatment 
naïve MS patients. And from Sievers et al, a similar conclusion can be reached about 
natalizumab, as treated patients also present a different miRNA expression compared to 
untreated RRMS patients and healthy controls. But in these two studies patients were already 
receiving their treatment when the first sample was withdrawn, so we don’t know how their 
miRNA expression was before treatment, and this represents the greatest flaw in both studies. 
We can’t be sure their miRNA expression before treatment was similar to the groups of 
untreated MS patients present in both studies. Another flaw in Sievers et al. is the small sample 
size, with only 10 individuals in the treatment group; this conditions low statistical power, low 
30 
 
reproducibility and it can both reduce the chance of detecting a true effect and also reduces the 
likelihood that a statistically significant result reflects a true effect (73).  
During this review we could only find one randomized, double blind placebo-controlled trial with 
treated MS patients that also analyzed miRNA expression. And from this study, even with flaws 
in its development and in need of new studies reproducing their results, we can answer more 
robustly to the question that concerns us: are there expression changes in miRNA after any 
pharmacological treatment of MS? Or maybe more importantly, is there any good quality 
evidence supporting this claim? To our opinion, we finally have something to hold on. Sanam 
Dolati as the main investigator and her team from the Tabriz University of Medical Sciences (East 
Azerbaijan Province, Iran) have put an effort to design two studies with miRNA expression 
analysis exactly before starting the treatment they are testing and after a reasonable time from 
baseline (6 months). And the findings are encouraging. After treatment with nanocurcumin, 
several miRNAs related to immunological mechanisms that directly impact MS pathogenesis are 
upregulated or downregulated in the direction to their normal status, for example miR-106 and 
miR-19b (necessary for B cell development), which are typically downregulated in MS patients, 
after treatment with nanocurcumin are significantly upregulated (2.23±0.88 and 1.55±0.23 fold 
respectively) compared with baseline. 
Another question we asked ourselves at the beginning of this review is if is there any similitude 
between expression changes in conventional disease modifying therapies and alternative 
therapies in MS. The only miRNAs that show a significant change in expression in a widely used 










These results suggest that some changes in miRNA expression can coincide between treatments, 
but this doesn’t mean much on its own.  
One question was if clinical trials support the value of miRNAs as biomarkers for treatment 
response in multiple sclerosis. We can intuit it is, at least in MS patients with mild disability; in 
Sanam Dolati et al. Dec 2018 EDSS changes were measured before and after treatment. In this 
study there was as significant reduction from 1.77±0.33 to 0.98±0.29 in the final EDSS score. This 
is encouraging, as the result was significantly different from the placebo group at endpoint.  





et al. May 2012. 
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miR-19b Upregulation* Upregulation** 
miR-106b Upregulation* Upregulation** 
Table 7. miRNA expression changes with different treatments. 
*Compared with untreated RRMS patients.  




On the other hand, In Sanam Dolati et al. July 2018 EDSS is depicted as <5/5 at baseline but there 
is no further analysis, in Sievers et al. EDSS status is not shown and in Waschbisch et al. they 
describe the scores by group, but made no longitudinal comparation. So, in light that we made 




The most important question in this review is if miRNAs are useful biomarkers for the treatment 
response in MS. After revision of the selected papers and specific literature about the use of 
miRNA as biomarkers, we’d have to change the word “useful” and replace it with “promising”. 
miRNAs have been investigated as MS biomarkers for the past 10 years but the field is still in its 
first steps, mainly because of the lack of strong studies evaluating their true potential. It will be 
fundamental for this line of investigation to develop well designed prospective studies with the 
right objectives, mainly well-defined cohorts with sufficient sample size, blinding of personnel 
and outcome assessors, and invariably a meticulous management of all the obtained data to 
establish the right miRNAs as biomarkers. A very important part of all this effort needs to be put 
in standardization of the processes used to assess miRNA expression, from the sample 
withdrawal to each step of processing and analysis, for all this data to be as comparable as 
possible with other publications. Of course, all this evidence will not be useful if validation 
studies are not carried on to add strength to a generalization of their use.  
Another interesting line of investigation would be the use of miRNAs as therapeutic targets, as 
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Figure 1. MicroRNAs differentially expressed in untreated RRMS patients (n=50) compared with 












































Figure 2. MicroRNAs differentially expressed in untreated RRMS patients (n=50) 
compared with healthy controls (n=35) and in the group treated with nanocurcumin 
(n=20). 
















































Figure 5. Hierarchy of research design according to the USPSTF. (57) 
 
Figure 4. SIGN levels of evidence. (56) 
 
Figure 6. Clinical endpoints after treatment. (66) 
 
